1109 related articles for article (PubMed ID: 23466307)
1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
Sangro B; Gomez-Martin C; de la Mata M; Iñarrairaegui M; Garralda E; Barrera P; Riezu-Boj JI; Larrea E; Alfaro C; Sarobe P; Lasarte JJ; Pérez-Gracia JL; Melero I; Prieto J
J Hepatol; 2013 Jul; 59(1):81-8. PubMed ID: 23466307
[TBL] [Abstract][Full Text] [Related]
2. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Duffy AG; Ulahannan SV; Makorova-Rusher O; Rahma O; Wedemeyer H; Pratt D; Davis JL; Hughes MS; Heller T; ElGindi M; Uppala A; Korangy F; Kleiner DE; Figg WD; Venzon D; Steinberg SM; Venkatesan AM; Krishnasamy V; Abi-Jaoudeh N; Levy E; Wood BJ; Greten TF
J Hepatol; 2017 Mar; 66(3):545-551. PubMed ID: 27816492
[TBL] [Abstract][Full Text] [Related]
3. Facing the dawn of immunotherapy for hepatocellular carcinoma.
Sprinzl MF; Galle PR
J Hepatol; 2013 Jul; 59(1):9-10. PubMed ID: 23571018
[No Abstract] [Full Text] [Related]
4. Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity.
Galun E; Terrault NA; Eren R; Zauberman A; Nussbaum O; Terkieltaub D; Zohar M; Buchnik R; Ackerman Z; Safadi R; Ashur Y; Misrachi S; Liberman Y; Rivkin L; Dagan S
J Hepatol; 2007 Jan; 46(1):37-44. PubMed ID: 17112624
[TBL] [Abstract][Full Text] [Related]
5. High TT virus load as an independent factor associated with the occurrence of hepatocellular carcinoma among patients with hepatitis C virus-related chronic liver disease.
Tokita H; Murai S; Kamitsukasa H; Yagura M; Harada H; Takahashi M; Okamoto H
J Med Virol; 2002 Aug; 67(4):501-9. PubMed ID: 12115995
[TBL] [Abstract][Full Text] [Related]
6. Specific CD8(+) T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis.
Moreno-Cubero E; Larrubia JR
World J Gastroenterol; 2016 Jul; 22(28):6469-83. PubMed ID: 27605882
[TBL] [Abstract][Full Text] [Related]
7. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
Ralph C; Elkord E; Burt DJ; O'Dwyer JF; Austin EB; Stern PL; Hawkins RE; Thistlethwaite FC
Clin Cancer Res; 2010 Mar; 16(5):1662-72. PubMed ID: 20179239
[TBL] [Abstract][Full Text] [Related]
8. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus.
Shindoh J; Hasegawa K; Matsuyama Y; Inoue Y; Ishizawa T; Aoki T; Sakamoto Y; Sugawara Y; Makuuchi M; Kokudo N
J Clin Oncol; 2013 Feb; 31(6):766-73. PubMed ID: 23129744
[TBL] [Abstract][Full Text] [Related]
9. [Chronic hepatitis C].
Grammatikos G; Sarrazin C
Dtsch Med Wochenschr; 2010 Dec; 135(50):2525-34; quiz 2535-8. PubMed ID: 21140330
[TBL] [Abstract][Full Text] [Related]
10. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis G infection and therapeutic response to interferon in HCV-related chronic liver disease.
Pramoolsinsap C; Poovorawan Y; Sura T; Theamboonlers A; Busagorn N; Kurathong S
Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):480-90. PubMed ID: 10437943
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the inhibitory effect of antisense oligodeoxynucleotides on the growth of hepatitis C-associated hepatocellular carcinoma cells in vitro.
Amin MA; Awadein MR; Gabr H
Chin J Dig Dis; 2005; 6(3):142-8. PubMed ID: 16045605
[TBL] [Abstract][Full Text] [Related]
13. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group.
Bernardinello E; Cavalletto L; Chemello L; Mezzocolli I; Donada C; Benvegnú L; Merkel C; Gatta A; Alberti A
Hepatogastroenterology; 1999; 46(30):3216-22. PubMed ID: 10626189
[TBL] [Abstract][Full Text] [Related]
14. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of hepatocellular carcinoma that occur after sustained virological response to interferon for chronic hepatitis C.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):122-8. PubMed ID: 16706823
[TBL] [Abstract][Full Text] [Related]
16. Low-dose IL-2 therapy reduces HCV RNA and HBV DNA: case report.
Tomova R; Antonov K; Ivanova A; Jacobs JJ; Koten JW; Den Otter W; Krastev Z
Anticancer Res; 2009 Dec; 29(12):5241-4. PubMed ID: 20044643
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of TT virus infection in patients with chronic hepatitis C.
Zein NN; Arslan M; Li H; Charlton MR; Gross JB; Poterucha JJ; Therneau TM; Kolbert CP; Persing DH
Am J Gastroenterol; 1999 Oct; 94(10):3020-7. PubMed ID: 10520863
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
[TBL] [Abstract][Full Text] [Related]
19. Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma.
Ikeda A; Shimizu T; Matsumoto Y; Fujii Y; Eso Y; Inuzuka T; Mizuguchi A; Shimizu K; Hatano E; Uemoto S; Chiba T; Marusawa H
Gastroenterology; 2014 Jan; 146(1):222-32.e35. PubMed ID: 24055508
[TBL] [Abstract][Full Text] [Related]
20. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
